Varlitinib tosylate
Modify Date: 2024-01-06 16:32:23
Varlitinib tosylate structure
|
Common Name | Varlitinib tosylate | ||
|---|---|---|---|---|
| CAS Number | 1146629-86-8 | Molecular Weight | 811.35 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C36H35ClN6O8S3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Varlitinib tosylateVarlitinib (ASLAN001) tosylate is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively[1]. |
| Name | Varlitinib tosylate |
|---|---|
| Synonym | More Synonyms |
| Description | Varlitinib (ASLAN001) tosylate is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 7 nM (HER1), 2 nM (HER2), 4 nM (HER4)[1] |
| In Vitro | 在使用过度表达 EGFR (A431) 或 ErbB-2 (BT474) 的肿瘤细胞进行的基于细胞的测定中，Varlitinib tosylate (ARRY-334543) 有效抑制底物磷酸化。 Varlitinib tosylate 被证明对 EGFR/ErbB-2 具有高度选择性，并且在针对一组 104 种激酶进行筛选时未显示任何显着活性[2]。 |
| In Vivo | Varlitinib tosylate 可有效抑制肿瘤生长，在每天两次 100 mg/kg 的剂量下可使肿瘤完全消退。Varlitinib tosylate 处理五天后，HER1-3、RAS/RAF/MEK/MAPK、p70S6K、S6 核糖体、4EBP1、Cdk-2、Cdc-2 和视网膜母细胞瘤的磷酸化受到强烈抑制。Varlitinib tosylate 处理导致生存素显着减少，同时 Caspase 3 裂解产物增加[1]。在小鼠异种移植模型中，Varlitinib tosylate（25、50、100 mg/kg）通过口服给药，每天两次，持续 21 天，在 A431 衍生肿瘤中表现出显着的剂量相关肿瘤生长抑制[2]。 |
| References |
| Molecular Formula | C36H35ClN6O8S3 |
|---|---|
| Molecular Weight | 811.35 |
| Exact Mass | 810.136719 |
| N-[3-Chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]-4,6-quinazolinediamine 4-methylbenzenesulfonate (1:2) |
| 4,6-Quinazolinediamine, N-[3-chloro-4-(2-thiazolylmethoxy)phenyl]-N-[(4R)-4,5-dihydro-4-methyl-2-oxazolyl]-, 4-methylbenzenesulfonate (1:2) |
| Varlitinib tosylate |